Preclinical Evaluation of <sup>99m</sup>Tc-Labeled GRPR Antagonists maSSS/SES-PEG<sub>2</sub>-RM26 for Imaging of Prostate Cancer
Background: Gastrin-releasing peptide receptor (GRPR) is an important target for imaging of prostate cancer. The wide availability of single-photon emission computed tomography/computed tomography (SPECT/CT) and the generator-produced <sup>99m</sup>Tc can be utilized to facilitate the us...
Main Authors: | Ayman Abouzayed, Sara S. Rinne, Hamideh Sabahnoo, Jens Sörensen, Vladimir Chernov, Vladimir Tolmachev, Anna Orlova |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/2/182 |
Similar Items
-
The GRPR Antagonist [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
by: Ayman Abouzayed, et al.
Published: (2023-05-01) -
Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
by: Ayman Abouzayed, et al.
Published: (2020-10-01) -
Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer
by: Christina Baun, et al.
Published: (2020-12-01) -
Evaluation of maSSS/maSES-PEG2-RM26 for their potential therapeutic use after labeling with Re-188. Could their [99mTc]Tc-labeled counterparts be used to estimate dosimetry?
by: Panagiotis Kanellopoulos, et al.
Published: (2025-01-01) -
<sup>68</sup>Ga-Labeled [Leu<sup>13</sup>ψThz<sup>14</sup>]Bombesin(7–14) Derivatives: Promising GRPR-Targeting PET Tracers with Low Pancreas Uptake
by: Lei Wang, et al.
Published: (2022-06-01)